Tejara Capital Ltd Invests $11.24 Million in Establishment Labs Holdings Inc. $ESTA

Tejara Capital Ltd purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 130,979 shares of the company’s stock, valued at approximately $11,239,000. Establishment Labs comprises about 4.6% of Tejara Capital Ltd’s investment portfolio, making the stock its 3rd largest holding.

Several other institutional investors have also added to or reduced their stakes in the company. Vise Technologies Inc. acquired a new position in Establishment Labs in the 2nd quarter valued at $327,000. BlackRock Inc. bought a new position in Establishment Labs during the 2nd quarter worth $135,752,000. Deutsche Bank AG acquired a new stake in shares of Establishment Labs during the second quarter worth $10,996,000. Rice Hall James & Associates LLC acquired a new stake in shares of Establishment Labs during the second quarter worth $48,134,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Establishment Labs during the second quarter worth $5,848,000. 72.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on ESTA shares. TD Cowen lifted their price objective on shares of Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. BTIG Research raised their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Needham & Company LLC lifted their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs presently has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Stock Down 5.1%

Shares of NASDAQ ESTA opened at $71.52 on Friday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. Establishment Labs Holdings Inc. has a 52 week low of $36.53 and a 52 week high of $97.59. The stock has a market capitalization of $2.13 billion, a P/E ratio of -54.60 and a beta of 1.07. The stock’s fifty day moving average is $86.38 and its 200 day moving average is $74.85.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) EPS. Sell-side analysts forecast that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.